Panthera Biopartners
Shereen Al Laham has been working in the healthcare industry since 2018. Shereen started as a Research Assistant at Sheffield City Council, where their duties included conducting interviews and focus groups with stakeholders in healthcare, qualitative analysis of interview transcripts and questionnaires using Nvivo, and analysis of quantitative data gathered from online consultation. In 2019, they became a Community Pharmacy Dispenser at the NHS, where they ensured a satisfactory customer experience, handled patients' health problems through OTC drugs and suitable counselling, and managed the supply chain of drugs, procurement logistics, and GSP. Shereen also held positions as a Clinical Pharmacy Attachment at The Royal Marsden NHS Foundation Trust, a Research Associate (Consultant) at Aceso Global Health Consultants Limited, a Research Fellow at UCL, an Honorary Research Fellow at Public Health England, and a Co-Founder at Totawell. In 2021, they took on the role of Interim Public Health Officer at NHS Kent & Medway Clinical Commissioning Group and Researcher at London School of Hygiene and Tropical Medicine, U. of London. Shereen is currently working as a Clinical Project Manager at Panthera Biopartners.
Shereen Al Laham obtained their Doctor of Pharmacy (PharmD) from AlMaarefa colleges between 2011 and 2017, specializing in Pharmacy. In 2017, they completed their Master of Public Health - MPH from The University of Sheffield, focusing on Management and Leadership. Shereen also holds certifications from APMG International, including AgilePM Foundation and AgilePM Practitioner, obtained in February 2022. Additionally, they have a Foundation of Clinical Research certification from the King Abdullah International Medical Research Center (KAIMRC), obtained in March 2015.
This person is not in any offices
Panthera Biopartners
1 followers
Panthera Biopartners, established in 2019, is a leading UK-based Site Management Organisation (SMO) specialising in patient recruitment and the execution of clinical trials across various therapeutic areas. Founded by Dr Ian Smith, the originator of Synexus, and Professor John Lyon, a former global executive at Covance, Panthera has rapidly expanded its network to include dedicated clinical trial sites in major UK cities such as Glasgow, London, Manchester, Preston, Sheffield and York The organisation's mission is to enhance healthcare accessibility by conducting clinical research that integrates diverse insights and expertise. Panthera is committed to maintaining rigorous ethical standards and contributing to medical advancements that positively impact health and well-being. Panthera's management team comprises experienced professionals with extensive knowledge in conducting clinical trials across multiple therapy areas and countries. Key figures include Dr Ian Smith (Co-Founder, Director, and Chief Medical Officer), Stuart Young (Chief Executive Officer), and Chris Dodd (Chief Commercial Officer). In October 2024, Panthera became the first UK clinical trial site organisation to join Parexel’s Site Alliance Vaccine Network, a global consortium of high-performing clinical trial sites. This collaboration underscores Panthera's exceptional performance in patient recruitment and its strong partnership with Parexel. Panthera's dedication to innovation and excellence was recognised in October 2023 when it was named Pharma Research Centre of the Year at the Pharma Industry Awards UK. The award highlighted Panthera's innovative SMO model, which emphasises rapid start-up times, access to a vast pool of prequalified patients, and the digitisation of patient engagement processes.